Latest receivables for 603087.SS: $980M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2026), 603087.SS shows a receivables of $980M. That compares with $560M in the prior-year period — up 75.5% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 603087.SS's receivables is now $980M (was $560M) — a 75.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Gan & Lee Pharmaceuticals. is outperforming or lagging.
Tracking 603087.SS's receivables over time shows whether Gan & Lee Pharmaceuticals. is scaling, shrinking, or reshaping that part of the business. The current reading is $980M That compares with $560M in the prior-year period — up 75.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Gan & Lee Pharmaceuticals.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $980M) with ownership activity and broader fundamentals.